Jeff oversees the Business Development, Finance and External Communication functions at Surface Oncology. He is a seasoned financial and business development executive with over 15 years of experience. Prior to Surface, he was the CFO of Voyager Therapeutics where he led multiple functions, including finance and business development, for the company. At Voyager, Jeff led the company through multiple strategic collaborations and financings, including an $845 million partnership with Sanofi Genzyme and a $73 million IPO. Previously, Jeff spent nearly a decade on Wall Street, where he was most recently a Managing Director at Evercore Partners where he advised on more than $100 billion in M&A and licensing transactions. Jeff began his career as a research scientist in the fields of musculoskeletal biology and gene therapy. He serves on the Board of Vaccinex. Jeff earned his B.A. in Biology, M.S. in Microbiology / Immunology, M.S. in Pathology / Molecular Medicine as well as his M.B.A. from the University of Rochester.